دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
doi : 10.1016/S2665-9913(21)00418-5
Volume 4, Issue 3, March 2022, Pages e154-e155
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries
doi : 10.1016/S2665-9913(21)00368-4
Volume 4, Issue 3, March 2022, Pages e160-e163
Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab
doi : 10.1016/S2665-9913(21)00393-3
Volume 4, Issue 3, March 2022, Pages e163-e166
Thank you to our peer reviewers in 2021
doi : 10.1016/S2665-9913(22)00037-6
Volume 4, Issue 3, March 2022, Pages e168-e169
Health-care workers recovered from natural SARS-CoV-2 infection should be exempt from mandatory vaccination edicts
doi : 10.1016/S2665-9913(22)00038-8
Volume 4, Issue 3, March 2022, Page e170
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1
doi : 10.1016/S2665-9913(22)00027-3
Volume 4, Issue 3, March 2022, Pages e171-e172
Severe COVID-19 as a virus-independent immunothrombotic process
doi : 10.1016/S2665-9913(22)00033-9
Volume 4, Issue 3, March 2022, Pages e172-e173
Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply
doi : 10.1016/S2665-9913(22)00031-5
Volume 4, Issue 3, March 2022, Page e173
Correction to Lancet Rheumatol 2021; 3: e789–97
doi : 10.1016/S2665-9913(22)00025-X
Volume 4, Issue 3, March 2022, Page e174
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
doi : 10.1016/S2665-9913(21)00394-5
Volume 4, Issue 3, March 2022, Pages e177-e187
The STAR care pathway for patients with pain at 3 months after total knee replacement: a multicentre, pragmatic, randomised, controlled trial
doi : 10.1016/S2665-9913(21)00371-4
Volume 4, Issue 3, March 2022, Pages e188-e197
